NCT01738139 2024-03-21Ipilimumab and Imatinib Mesylate in Advanced CancerM.D. Anderson Cancer CenterPhase 1 Completed68 enrolled
NCT02304458 2023-10-17Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasNational Cancer Institute (NCI)Phase 1/2 Completed140 enrolled 23 charts